Skip to content

Multicenter Retrospective Cohort Study on the Efficacy and Safety of Transjugular Intrahepatic Portosystemic Shunt in Treating First-Onset Severe Ascites in Cirrhosis

Multicenter Retrospective Cohort Study on the Efficacy and Safety of Transjugular Intrahepatic Portosystemic Shunt in Treating First-Onset Severe Ascites in Cirrhosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600119998
Enrollment
Unknown
Registered
2026-03-06
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cirrhosis

Interventions

Transjugular Intrahepatic Portosystemic Shunt group:None
LVP+HA group:None

Sponsors

The Second Affiliated Hospital of Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years old, gender not limited; 2. Patients diagnosed with liver cirrhosis and experiencing significant ascites for the first time; The definition of the first large amount of ascites is: in patients with liver cirrhosis, the following conditions occur for the first time: obvious abdominal distension, positive body movement dullness, and possible abdominal distension or even umbilical hernia formation; Ultrasound shows that lower abdominal fluid occupies the entire abdominal cavity, while the middle abdomen is filled with ascites, with a depth greater than 10cm; 3. Patients receiving TIPS or LVP+HA treatment; 4. Patients with relatively complete clinical data.

Exclusion criteria

Exclusion criteria: 1. Patients with severe liver, kidney, and heart multiple organ failure; 2. Merge liver cancer and leukemia; 3. Grade 2 or above hepatic encephalopathy (indicated by drowsiness); 4. Serum bilirubin concentration greater than 5 mg/dl (86 µ mol/L)/MELD>16.

Design outcomes

Primary

MeasureTime frame
liver transplant free survival rate;

Secondary

MeasureTime frame
Reaction of ascites;The impact on liver and kidney function;Incidence and duration of hepatic encephalopathy (HE);Abdominal puncture frequency and ascites volume;Diuretics usage and dosage;Abdominal infection;

Countries

China

Contacts

Public ContactXu Zhengguo

The Second Affiliated Hospital of Army Medical University

xzgdy@tmmu.edu.cn+86 188 7511 5346

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026